Nationwide alert in China for the faulty rabies vaccine

The second largest drug manufacturing company “ Changchun Changsheng Life Sciences” were found guilty for violated national standards including usage of expired fluids and falsified production dates to produce rabies vaccine. Rabies Vaccines manufactured in China was widely exported to countries including India too.

This recent scandal of faulty Rabies Vaccines creating panic and especially in China. After taking a quick action on this, country has started a nationwide campaign to provide health consultation and free inoculation of rabies vaccines.

In India, the Drug Controller General of India also ordered immediately to withdraw rabies vaccines from the market and also banned their imports from Changchun Changsheng Life Sciences.

Healthcare centers, institutions and disease control centers have started providing consultation services for those who received or used rabies vaccines made by the company. 36,482 hospitals and health centers are designated by the China government to provide consultation. No life loss has been reported yet from the patients who injected with the faulty Rabies vaccines.

According to the report, Changchun Changsheng making use of expired fluids and false production dates is in continuity since April 2014 and had violated rules on production management and national drug standards for the vaccines.

China National Health Commission and the State Drug Administration are actively working on the issue and created an inoculation plan for patients who have injected rabies vaccines from the Changchun Changsheng company. And the patients who are getting treated and those whose required course are not yet completed can switch to vaccines from other companies at no charge.

China government also start giving free re-inoculated who have completed their courses less than a year ago and vaccination institutions will provide tracking, observation, and advisory services.

Related Posts

Commissioner FDA reviews enforcement measures

Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

Piramal Pharma Gets 3 USFDA Observations at US Facility

Piramal Pharma Gets 3 USFDA Observations at US Facility

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices